Here's Advertisement
Investment Overview
A MLP offering 9.4% cash distribution yield sounds attractive, and if financial projections see sustained growth in cash distribution, there is a strong case for investment.
This article will discuss why GasLog Partners (NYSE:GLOP) is an attractive MLP to conside
BofI(NASDAQ:BOFI) stock doesn't fit anybody's definition of "cheap."
To be more precise, it's trading at 2.9 times tangible book value (TBV). That's undeniably expensive for any bank; generally, you hope to see that ratio closer to 1.2 to 1.5 times TBV.
But you pay up for quality. H
Shutterstock
Fact: When interest rates rise, you need to be in dividend-growth stocks.
Proof: They’ve handily beaten the S&P 500 in the 17 months since the Federal Reserve put the zero-interest-rate era on ice.
In just a moment, I’ll show you 2 terrific off-the-radar dividend-growth plays to snap up now—and 2 surprising blue chips you’ll want to....More>>>
If you’re looking for good Warren Buffett stocks to buy, there’s no better option than Buffett’s former money guy. I’m talking, of course, about Lou Simpson, the long-time Geico portfolio manager, who retired at the end of 2010 after 31 years at the company, more than a third of them spent under Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B) ownership.
It’s....More>>>
I believe Valero Energy (NYSE:VLO) shares are currently an undervalued long-term buy at current levels, based on its high free cash flow yield of over 10% and significant discount to its fair/intrinsic value. Additionally, I believe the company will continue to enjoy high returns on capital invested because of its sustainable competitive advantages. In this article I will explain the company’s....More>>>
Although you wouldnt necessarily know it from the relative performance of other banks in its weight class, Farmers Capital (NASDAQ:FFKT) has taken some meaningful self-improvement steps over the last couple of years. These moves have put the company on a path toward better interest spreads, better efficiency ratios, and better growth prospects, all of which should support higher earnings and returns....More>>>
In this segment from the Motley Fool Money podcast, host Chris Hill is joined by Jason Moser of Million Dollar Portfolio, David Kretzmann of Hidden Gems Canada, and Aaron Bush of Motley Fool Rule Breakers to discuss the recent accounting woes at WageWorks (NYSE:WAGE). The provider of employee benefit plans has launched an investigation after reporting it inflated some of its profit and revenue figures.....More>>>
Hospitals may soon have to post their standard prices for patients online, under a proposed rule unveiled Tuesday by the Trump administration.
Also, the administration is seeking comments on how to stop so-called surprise billing — when patients are charged after unknowingly being seen by out-of-network providers — and how to give patients better information about the out-of-pocket....More>>>
Is volatilityfinally back! You bet your assets it is. The Dow fell well over 600 points into the closing bell, and the major equity indexes followed suit. As a reminder, investors have been stating openly that they wanted a big pullback so they could buy more of their favorite stocks. The only problem is that most retail investors usually freeze during sell-offs because they are scary while they....More>>>
Investors sold shares of Celgene (NASDAQ:CELG) on strength during trading hours on Friday. $125.14 million flowed into the stock on the tick-up and $200.18 million flowed out of the stock on the tick-down, for a money net flow of $75.04 million out of the stock. Of all stocks tracked, Celgene had the 12th highest net out-flow for the day. Celgene traded up $2.16 for the day and closed at $84.54
CELG....More>>>
Chimeric antigen receptor T-cell (CAR-T) therapies and gene therapies are hot commodities these days. But some small biotechs developing CAR-T drugs and gene therapies are hotter than others.
Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past,....More>>>
Sometimes, earnings grow faster than stock prices. And other times,growth stocks go on sale even though revenue is still climbing. In both cases, P/E ratios can fall to levels that make growth stocks look more like value stocks. When that happens, buying shares can lead to market-beating returns, so we asked these three Motley Fool investors if there are any growth stocks on their radar that are....More>>>
bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.
Bluebird results: The only number that really matters
Metric
Q1 2018
Q4 2017
Quarter-Over-Quarter Change
Cash,....More>>>
Target Corporation (TGT) offers a perfect buying opportunity to long-term investors, as the company continues to generate optimistic results, while strong operational and timely business strategies will allow it to outperform the market headwinds. Retailers have experienced significant losses in the first half this year due to rising inflation, increasing costs, mounting competition and tightening....More>>>
Biotech hasn’t been a great place to invest your money in 2018.The iShares Nasdaq Biotechnology Index, after all, is down by over 4% at present, and summer has historically been a down time for this high-risk space. So, there’s little reason to believe a widespread rally is coming anytime soon.
Even against this dour backdrop, however, several former top biotech stocks have turned....More>>>
Some of the stocks that may grab investor focus today are:
Wall Street expects Celgene Corporation (NASDAQ: CELG) to report quarterly earnings at $1.96 per share on revenue of $3.46 billion before the opening bell. Celgene shares rose 1.87 percent to $87.00 in after-hours trading.
Weight Watchers International, Inc. (NYSE: WTW) reported stronger-than-expected results for its first....More>>>
Geron (GERN) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson’s (JNJ) subsidiary Janssen will make a long-awaited continuation decision as to whether it will proceed with development of....More>>>
American Republic Agrees to Acquire Funeral Insurer
5 Peeks at a Hot New Variable Annuity Guarantee Paper
4 Ways New York May Make DOL Look Like a Fiduciary Kitten
Drugmakers can provide free medication to patients who can’t afford their prescriptions after a major indu
The annual American Society of Clinical Oncology Conference kicks off Friday, June 1, 2018.Every year, thousands of healthcare professionals, scientists, and investors assemble in Chicago to hear about the latest scientific breakthroughs redefining cancer care. Over the course of this five-day co
In the part 1, part 2, and part 3 of the series, I have discussed growth drivers and on-going research programs for Celgene's (NASDAQ:CELG) key oncology products, Revlimid and Pomalyst. Beyond hematologic oncology, however, Celgene also has a strong presence in the solid tumor segment.
Cel
It is no secret that Celgene (NASDAQ:CELG) is thriving while improving the lives of patients with cancer and autoimmune diseases in the United States and around the world.
Celgene's recent outstanding performance has primarily been on the back of its workhorse, REVLIMID (lenalidomide), use
Keeping tabs on what iconic billionaire investors George Soros, Warren Buffett, and Carl Icahn are doing with their money can help you find new money-making ideas. What have Soros, Buffett, and Icahn been buying lately? According to reports,Celgene Corp (NASDAQ:CELG), Apple Inc. (NASDAQ:AAPL), an
Here's Advertisement